Print Page  Close Window

News Release

Emergent BioSolutions to Present at Upcoming Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 10, 2007--Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at the following two investor conferences over the next thirty day period.

-- The New York Society of Securities Analysts (NYSSA) Annual Biotech
    & Specialty Pharma Conference
   NYSSA Headquarters
   New York, NY.
   December 12, 2007
   Presentation Time: 10:55 am Eastern

-- J.P. Morgan 26th Annual Healthcare Conference
   St. Francis Hotel
   San Francisco, CA.
   January 9, 2007
   Presentation Time: 10:30 am Pacific

During these presentations, senior management will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

Webcasts of each of these presentations will be available both live and by replay. To access either the live or archived webcast for either presentation, please proceed to www.emergentbiosolutions.com, click on the "Investors" link and proceed to the "Webcasts & Presentations" section, beginning on the day of the specific presentation.

An archived replay of each webcast will be available 24 hours after the live presentation.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.


    CONTACT: Emergent BioSolutions Inc.
             Investors Contact:
             Robert G. Burrows
             Vice President, Investor Relations
             301-795-1877
             BurrowsR@ebsi.com
             or
             Media Contact:
             Tracey Schmitt
             Director, Corporate Communications
             301-795-1800
             SchmittT@ebsi.com

    SOURCE: Emergent BioSolutions Inc.